{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 08707dd8-9119-4f99-b4d8-46949569b4ee --><h2>Update</h2><!-- end field 08707dd8-9119-4f99-b4d8-46949569b4ee -->","summary":null,"htmlStringContent":"<!-- begin item 8d8faa95-71e6-48d2-a8f2-f7a5c714ce5a --><!-- end item 8d8faa95-71e6-48d2-a8f2-f7a5c714ce5a -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e8927bd5-6525-583c-a470-b151ed483a3f","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 02f09be3-4896-4760-be66-64d2335f2433 --><h3>New evidence</h3><!-- end field 02f09be3-4896-4760-be66-64d2335f2433 -->","summary":null,"htmlStringContent":"<!-- begin item ff00f38c-398a-4c57-904a-638b80dc4770 --><!-- begin field c86d89e2-7e57-4fb2-9289-31bc44f1f7dd --><h3>Evidence-based guidelines</h3><!-- end field c86d89e2-7e57-4fb2-9289-31bc44f1f7dd --><!-- begin field 22190a40-2db9-460a-83f9-c5f90572f153 --><p>No new evidence-based guidelines since 1 August 2020.</p><!-- end field 22190a40-2db9-460a-83f9-c5f90572f153 --><!-- begin field 4501fda6-4326-49f3-8edc-ac380f980b3b --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 4501fda6-4326-49f3-8edc-ac380f980b3b --><!-- begin field 354f84ae-10dc-4c4d-b8dc-45ee195d5b39 --><p>No new HTAs since 1 August 2020.</p><!-- end field 354f84ae-10dc-4c4d-b8dc-45ee195d5b39 --><!-- begin field 47bb15b9-18f2-4dcc-982e-84c02eea55c7 --><h3>Economic appraisals</h3><!-- end field 47bb15b9-18f2-4dcc-982e-84c02eea55c7 --><!-- begin field 337a7a35-ef51-4d4a-8c85-cc8f003ce6e3 --><p>No new economic appraisals relevant to England since 1 August 2020.</p><!-- end field 337a7a35-ef51-4d4a-8c85-cc8f003ce6e3 --><!-- begin field 49febea2-c3c9-48d5-90c8-d8d1cacd1ad7 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 49febea2-c3c9-48d5-90c8-d8d1cacd1ad7 --><!-- begin field f6fc67d9-fc22-4943-ac9e-2e8db5f024e5 --><p>No new systematic reviews or meta-analyses since 1 August 2020.</p><!-- end field f6fc67d9-fc22-4943-ac9e-2e8db5f024e5 --><!-- begin field 8bf8a6ec-0efe-4880-bed9-e2aab16c5538 --><h3>Primary evidence</h3><!-- end field 8bf8a6ec-0efe-4880-bed9-e2aab16c5538 --><!-- begin field e6ff0d27-244b-491d-998e-cb6f52b7b85c --><p>No new randomized controlled trials published in the major journals since 1 August 2020.</p><!-- end field e6ff0d27-244b-491d-998e-cb6f52b7b85c --><!-- end item ff00f38c-398a-4c57-904a-638b80dc4770 -->","subChapters":[]},{"id":"90db0ff2-7685-5d2d-ac96-fe20f25cbe58","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field ea843c0b-c725-47eb-80ae-747e51da592b --><h3>New policies</h3><!-- end field ea843c0b-c725-47eb-80ae-747e51da592b -->","summary":null,"htmlStringContent":"<!-- begin item 0c0e0442-b165-4a02-973a-bf74d070f8fb --><!-- begin field aa6a4d27-f257-4773-b065-64a44692b0f7 --><p>No new national policies or guidelines since 1 August 2020.</p><!-- end field aa6a4d27-f257-4773-b065-64a44692b0f7 --><!-- end item 0c0e0442-b165-4a02-973a-bf74d070f8fb -->","subChapters":[]},{"id":"e39557fa-c67a-550f-b77c-9a1fa5e02359","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 218617f0-cddf-438e-9fb9-890e2ab1e2a5 --><h3>New safety alerts</h3><!-- end field 218617f0-cddf-438e-9fb9-890e2ab1e2a5 -->","summary":null,"htmlStringContent":"<!-- begin item 0c2a6628-7d6b-4d8c-9511-b0fd312a3825 --><!-- begin field 5e212960-320d-46e6-9256-9cca81bb71a4 --><p>No new safety alerts since 1 August 2020.</p><!-- end field 5e212960-320d-46e6-9256-9cca81bb71a4 --><!-- end item 0c2a6628-7d6b-4d8c-9511-b0fd312a3825 -->","subChapters":[]},{"id":"474fcb59-2c84-5b76-95e8-b9cf42290811","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 87367ca3-7158-48ac-b31d-65ea5687f364 --><h3>Changes in product availability</h3><!-- end field 87367ca3-7158-48ac-b31d-65ea5687f364 -->","summary":null,"htmlStringContent":"<!-- begin item fb397243-50c5-447b-829d-758c822607bd --><!-- begin field 6aa0b06e-f297-4d2e-951e-aab9ea8ec902 --><ul><li>Ozanimod hard capsules, is an oral sphingosine-1-phosphate receptor modulator, licensed for the treatment of adults with relapsing remitting multiple sclerosis with active disease as defined by clinical or imaging features. See more <a href=\"https://www.medicines.org.uk/emc/product/11907/smpc\" data-hyperlink-id=\"b808696d-8df3-4194-95b4-ac7501018c2d\">here</a>.</li></ul><!-- end field 6aa0b06e-f297-4d2e-951e-aab9ea8ec902 --><!-- end item fb397243-50c5-447b-829d-758c822607bd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}